Immunomedics other research news
At the International Conference on Antibody Engineering in San Diego, IMMU reported progress in designing new immunoconjugates, using the carbohydrate site it discovered last year on monoclonal antibodies. The site is on the variable region of the B-cell lymphoma targeting antibody LL2. Because the site is distant from the antigen binding site, it does not interfere with the immunoreactivity of the antibody. Previously, attempts to link antibodies to drugs have interfered with the antibodies' targeting ability.
IMMU said it has been able to engineer this carbohydrate site onto antibody fragments, and it has also engineered a glycosylation site for carbohydrate attachment on the light chain variable region of its humanized, CDR-grafted Immu-14 monoclonal, which is aimed at the carcinoembryonic antigen present on 75 percent of solid tumors. ...